As one of the biggest pharmaceutical companies in the world, Merck (MRK 2.93%) is constantly battling generic drugmakers in court. Take a look at some of its recent annual or quarterly SEC filings and you're sure to see huge sections devoted to its patent litigation struggles against a number of companies.
Recently, Merck was able to protect its cholesterol drugs Zetia and Vytorin from earlier-than-expected competition from Mylan (MYL). In this video, health care analyst Max Macaluso discusses what happened and how these drugs fit into Merck's overall business.
